Effect of dobutamine on plasma potassium in congestive heart failure secondary to idiopathic or ischemic cardiomyopathy

Am J Cardiol. 1989 Apr 1;63(12):843-6. doi: 10.1016/0002-9149(89)90054-4.

Abstract

Dobutamine was administered in a dose of 10 +/- 1 micrograms/kg/min to 13 patients with severe idiopathic or ischemic dilated cardiomyopathy. Acute hemodynamic improvement was noted in all patients. All patients had a significant decrease in plasma potassium (4.6 +/- 0.1 to 4.2 +/- 0.2 mEq/liter, p less than 0.0001) at peak infusion. The decrease in potassium persisted for at least 45 minutes after discontinuing the infusion. Three patients had exacerbation of baseline ventricular arrhythmias that resolved with infusion discontinuation. Changes in plasma norepinephrine could not explain the potassium decrease or arrhythmia production, which also significantly decreased in these patients (771 +/- 123 to 524 +/- 73 pg/ml, p less than 0.01). It is concluded that dobutamine causes a significant decrease in plasma potassium and that the decrease persists at least 45 minutes after the infusion is discontinued.

MeSH terms

  • Arrhythmias, Cardiac / chemically induced
  • Cardiomyopathy, Dilated / complications*
  • Dobutamine / adverse effects
  • Dobutamine / therapeutic use*
  • Female
  • Heart Failure / blood
  • Heart Failure / drug therapy*
  • Heart Failure / etiology
  • Heart Failure / physiopathology
  • Hemodynamics / drug effects
  • Humans
  • Male
  • Middle Aged
  • Norepinephrine / blood
  • Potassium / blood*

Substances

  • Dobutamine
  • Potassium
  • Norepinephrine